We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

September 27, 2019

Digital Health Commercialisation and Preventative Health in Australia 

Commentary
Hanna Phelan
&

Digital health is up there in terms of the potential to transform healthcare as we know it. As one CEO of a digital health company said “when software enters an industry, in the early days people discredit it for child’s play - a toy or a game, but one day incumbents wake up and they can’t recognize their industry anymore and won’t know where to start”. We share this belief as do many of our colleagues in this burgeoning industry.


However, while product and service innovations in digital health have been plenty, impact at scale on patient outcomes, business outcomes, and population outcomes have yet to be realized and this makes us ponder - will this ever happen and when?


Finding a way to scale digital health solutions in critical, the industry needs it badly to keep the enthusiasm (and investment flowing). As we reflect on the digital health industry’s handful of successes and many failures, a few themes have stood out. 


Be forewarned that this isn’t a big reveal. From our POV scale in digital health will require 5 key elements: 

  1. Companies that tenaciously focus on delighting the end-user (patient/provider)
  2. Stakeholders that ensure value is created and shared with the ecosystem (patient, provider, payer, channel)
  3. Creativity in constructing a business model within existing payment structures and/or with novel models native in the SaaS industry
  4. Integration of solutions without friction into the healthcare ops/IT workflow and 
  5. Agility in commercialization capabilities as much in SW development. 


This may sound like common sense, but for some healthcare industry veterans, these concepts are farther afield than for someone in tech. We believe success will accrue to those digital health companies who can take these imperatives that are common sense and put them into common practice within their organizations and within the healthcare industry.


In July 2019, we gathered at The Royal Children's Hospital, Melbourne with a hand-selected group of the HealthXL community to discuss why the rest of the world should be looking at Australia for digital health.

Read on for the distilled insights from the day and the thought leaders who took part in the following conversations: 


  1. Digital health commercialisation and the Australian opportunity
  2. Precision health: Predicting and preventing disease — not just treating it


Digital Health Commercialisation and the Australian Opportunity 

The HealthXL Community prides itself on bringing together the most relevant and diverse expertise - this conversation was no exception with representatives including Australian clinicians, governmental organisations, pharma, tech companies, payers and foundations: 

Group participants:


As the group discussed Digital Health commercialisation, 3 key takeaways emerged: 

  1. Defining customer and revenue streams early is essential for commercialisation success to be an option. Understanding how the money flows (and achieving mutual benefit for users, customers and payers)
  2. Solving a real clinical or social  problem as well as a real financial problem is key. Being guided by the problem and co-designing  solutions with this understanding front and center in close collaboration with key stakeholders sets the stage for success
  3. Being absolutely clear on the value propositions for both the user or users and the customer. They are likely to be different value propositions.


Beyond the above, there is also a point to be made around the ability of companies to be agile in their go-to-market approaches. Digital Health products, being software based, inherently are meant to evolve and improve with customer use. Designing effective pilots, learning and iteratively deploying the product is critical. Companies that embrace this and don't go with a heavily fixed product may be more likely to succeed in realising commercialisation success. 


Additionally there is the matter of customer success and ongoing engagement. Digital health solutions are largely intended to be less transactional than drugs or medical devices. Ensuring customers use the product and realise benefits is key to continued engagement and value. What good is a diabetes disease management program if patients don't use it or doctors don't change their interventions based on this. Companies must invest and prioritise ongoing customer success across the B2B2C touch points - patient engagement, provider workflow and payer/hospital business process.


The Australian Advantage 

During the conversation in Melbourne, Australia was regarded (unsurprisingly) as being advantageous for successful digital health commercialisation on a number of levels. Some of the main reasons Australia was regarded as an attractive opportunity for DH commercialisation included:


Defining Success in DH Commercialisation 

So how do we measure commercialisation success? The group saw one form of commercial success iIn cases where large incumbent organisations in health care buy and develop digital health solutions to bolster their pre-existing offerings the group saw one form of commercial success. Beyond this, the development of evidence of efficacy for a product should be held in high regard alongside consensus that evidence of commercial evidence must be gathered alongside clinical  patient outcome metrics.


While the above points drew consensus, there was a healthy tension in the group between the commercial companies and not-for-profit organisations. Commercial representatives focused heavily on implementation and sustainable business success, while the non-for-profit representatives veered towards defining success as grant funded short-term implementation. 


As with any digital health conversation, finding a shared vocabulary and defining an understanding of certain terms and concepts was crucial. Some of those debated included:


The group was in consensus that securing early seed funding could be a false marker of success and that implementation/uptake at scale was key. The group also agreed that this ideally was to be dependent on an evidence-based cost benefit assessment, and funding was also required to adequately address clinical evidence needs. After all, tools that improve patient outcomes are really the ultimate goal of digital health interventions. 

Early Digital HealthSuccess Stories 

The group had very different definitions of ‘success’ depending on their own organisations business models. The more commercial sector participants cited business success as well as patient impact as key criteria, while the Charities and other institutions expressed a strong interest in impact measures with followed by business sustainability and to a lesser extent profit. Two main examples of varied successes were discussed:


  1. Seer Medical – This was initially developed by a small group of clinicians at St Vincent's Hospital Melbourne who wanted to monitor epilepsy in the home. A real need was identified for home monitoring, and from there, the initiative successfully tapped into existing medicare reimbursement codes. As a result of this effort being rolled out it, there was a reported reduction in unnecessary use of in-hospital resources. The Seer epilepsy diagnostic service is Medicare bulk-billed meaning patients do not have any out-of-pocket expenses. In 18 months, the company has grown to 60+ employees.
  1. Movember Patient Support: Through interviews with newly diagnosed cancer patients the Movember Foundation team found that a major pain-point for patients was the quick transition from consulting with a neuro-oncologist, to transitioning into self-management and ambulatory environments. Based on this, Movember developed an app that provides support for these patients with a peer-to-peer model. While starting with patient need, evidence is obviously key, so this intervention is currently undergoing RCT. 

To maintain trust in the digital health industry, regardless of your definition of success, it is important to have clear measurable end points  and claims stated up front and then satisfy them. If we can be consistent in this, we will have a stronger industry. 


Australia has a great ecosystem to navigate complex value chains. Money flow is key (understanding where and how the money flows in the healthcare system in order to build a sustainable solution) and ultimately we're aiming for a triple win - improve access to outcomes, users love using it, customers are happy to pay for it. This conversation brought up some great insights, however also raised outstanding questions including the question of where does solution trust sit in the measurement of success.



Precision health: Predicting and preventing disease — not just treating it

Through initiatives in precision health, it is hoped that we will be able to harness the availability of very large data sets and our ability to interpret and analysze that data to gain a more sophisticated understanding of the determinants of health and well-being, as well as specific risk factors and approaches for individual patients.


Group Participants: 


In Australia, it is acknowledged broadly that there is an ability to do high quality trials rapidly. The Australian health system is high performing and researchers are embedded within the means to prototype develop and test digital technology in a timely fashion and an ability for setting up the technology for scaling and contractual studies in global markets.


Given this context, CSIRO has invested in the Precision Health Future Science Platform. However, the organisations representations recognise the need to engage with partners and collaborators and in particular actively seek input across the Health Ecosystem with some challenge points: 



The Precision Health group at the Melbourne gathering took the approach of splitting the group into a debate style conversation with the affirmative highlighting the positive of how digital health can deliver truly personalised, preventive health and others highlighting why it may not deliver and why it hasn’t happened already. And while all participants appeared to be pragmatic optimists, there was a relatively long list ofn these goals that would be challenginga challenge to achieve.


For the discussion on the against the overarching message was “digital is tool and enabler for health, it will not solve all; and we can’t yet do the simple stuff, what makes us think we can do this!


Further details from the against side of the group that came through in the discussion were:


On the positive side the group discussed again how digital is not the entire solution and highlighted the strong requirement of human touch and interaction. In Australia, there have been distributed care models that demand in place care and support, through data integration healthcare stakeholders such as CSIRO now have access to data they never had previously. CSIRO are using Big Data to reduce variation in care, reduce unnecessary costs, distance is no longer the barrier it has been, and are getting better at good ROI. 


There are active discussions on how regulation, privacy and ethics will enable the move towards Digital Preventive Health solutions as digital natives start to engage with the Health system, expecting digital solutions. Finally, the group agreed to continue this discussion about what is required to enable this in Australia, and how healthcare in Australia can come together to ensure precision health reaches everybody. 


Co Authors:

Grace Lethlean @ AND Health

Nathan O'Callaghan @ CSIRO 

Vijesh Unnikrishnan @ ZS associates

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.